arrow
S

Salvatore Perrone

department of hematology
H指数:18
被引数:996

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Incidence of infections in patients treated with rituximab for autoimmune disorders of hematological Interest or non-Hodgkin lymphoma

利妥昔单抗治疗血液学相关自身免疫性疾病或非霍奇金淋巴瘤患者的感染发生率

2026-05-090
OAAI
Asciminib and pulsed ATRA as post-remission therapy in T315I mutated PML-RARA-positive blast crisis of chronic myeloid leukemia

Asciminib和脉冲式ATRA作为T315I突变PML-RARA阳性慢性粒细胞白血病急变期的缓解后治疗

2026-02-170
OAAI
Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351.

根据SIE/SIES/GITMO标准对治疗相关和aml-mrc接受CPX-351的适应性分类的影响。

2025-12-110
OAAI
Correction: Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia

更正:CPX-351在60岁以下继发急性髓系白血病患者中的真实世界多中心疗效分析

2025-12-040
OAAI
Effectiveness of Gilteritinib Beyond Second-Line Therapy in Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: A Real-World Multicenter Study of 171 Patients

Gilteritinib在二线治疗后的有效性:一项关于171例复发/难治性FLT3突变急性髓系白血病患者的真实世界多中心研究

2025-11-010
OAAI
Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia

真实世界多中心分析CPX-351在60岁以下继发性急性髓系白血病患者中的疗效

2025-10-260
OA
Real World Study on the Best CPX-351 Treatment Duration and Timing for Allogeneic Stem Cell Transplantation

真实世界研究:异基因干细胞移植的最佳CPX-351治疗时长与时机

2025-09-240
OAAI
Posaconazole and midostaurin in patients with FLT3-mutated acute myeloid leukemia: Pharmacokinetic interactions and clinical facts in a real life study
2023-07-282
OAAI
Impact of gemtuzumab ozogamicin consolidation on hematopoietic stem cells (HSCs) mobilization in AML: analysis of 20 patients

gemtuzumab ozogamicin巩固对AML造血干细胞 (hsc) 动员的影响: 20例患者分析

2023-02-161
PRE